Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis
Open Access
- 3 November 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (1) , 568-574
Abstract
Checkpoint kinase 1 (CHK1) and p53 are involved in cell‑cycle checkpoint, and cellular response to DNA damage. CHK1 and p53 are overexpressed in bladder urothelial carcinoma (BUC); however, a clear elucidation on their interaction and influence in the progress of BUC is absent. The aim of the present study was to examine the correlation between CHK1 and p53 in BUC, and analyze their value as therapeutic targets and prognostic indicators in BUC. A clinically annotated cohort of 110 patients with BUC was identified retrospectively. EnVision‑based immunohistochemistry and western blot analysis of the aforementioned DNA repair proteins were conducted on formalin‑fixed‑paraffin‑embedded or frozen tissues from the primary tumor. A total of 45 peritumoral tissue cases were assessed similarly as the control group. In the cohort of 110 patients with BUC, a significant overexpression of CHK1 and p53 was observed in primary compared with the peritumoral tissues (P<0.05). CHK1 and p53 demonstrated a positive correlation in BUC, and both were positively associated with the histological grade, clinical pathological staging, lymphatic metastasis and the 5‑year survival rate (P<0.05). However, CHK1 and p53 were not associated with sex, age, tumor diameter, single/multiple sites or incipient/recurrence. The overexpression of CHK1 and p53, and their synergistic interaction were putatively correlated with the physiology of BUC that may be deemed as potential therapeutic targets and prognostic indicators.Keywords
This publication has 29 references indexed in Scilit:
- microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancerInternational Journal of Cancer, 2013
- Lack of progress in bladder cancer—what are the obstacles?Nature Reviews Urology, 2012
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Urothelial carcinoma of the bladder: definition, treatment and future effortsNature Reviews Urology, 2011
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugsMolecular Oncology, 2011
- Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experienceBJU International, 2010
- ATR and Chk1 Suppress a Caspase-3–Dependent Apoptotic Response Following DNA Replication StressPLOS Genetics, 2009
- The genetics of the p53 pathway, apoptosis and cancer therapyNature Reviews Drug Discovery, 2008
- Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1–dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlicMolecular Cancer Therapeutics, 2007
- Chk1 Requirement for High Global Rates of Replication Fork Progression during Normal Vertebrate S PhaseMolecular and Cellular Biology, 2006